Aleksander Krag on the utility of PEth for subclassifying individuals at risk of steatotic liver disease
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Aleksander Krag on the utility of PEth for subclassifying individuals at risk of steatotic liver disease
-
ナレーター：
-
著者：
概要
Steatotic liver disease labels hinge on alcohol intake, but self-report is often inaccurate. In this episode, Aleksander Krag (Odense University Hospital) discusses a large Danish study using phosphatidylethanol (PEth), a direct blood biomarker of recent drinking, showing substantial underestimation and potential reclassification from MASLD to MetALD/ALD.
Click here to read the full article:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00187-6/fulltext
Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.
You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.
Continue this conversation on social!
Follow us today at...
https://bsky.app/profile/lancetgastrohep.bsky.social
https://www.linkedin.com/company/langastro/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://youtube.com/thelancettv